CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum
CNS Pharmaceuticals (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, has announced its participation in the 24th Annual Biotech in Europe Forum. John Climaco, the company's CEO, is scheduled to present on Wednesday, September 25, 2024, at 1:55 PM CEST in Basel, Switzerland.
The presentation will be available as a video webcast on demand for registered attendees through the conference presenters portal. Additionally, the company's management team will be available for in-person one-on-one meetings with qualified investors attending the conference.
This event provides CNS Pharmaceuticals with an opportunity to showcase its developments in primary and metastatic cancer treatments, potentially attracting investor interest and fostering industry connections.
CNS Pharmaceuticals (NASDAQ:CNSP), una società biotecnologica impegnata nello sviluppo di nuovi trattamenti per i tumori cerebrali e del sistema nervoso centrale, ha annunciato la sua partecipazione al 24° Forum annuale Biotech in Europa. John Climaco, CEO dell'azienda, è programmato per presentare mercoledì 25 settembre 2024, alle 13:55 CEST a Basilea, Svizzera.
La presentazione sarà disponibile come video webcast on demand per gli ospiti registrati tramite il portale dei relatori della conferenza. Inoltre, il team di gestione dell'azienda sarà disponibile per incontri individuali di persona con investitori qualificati presenti alla conferenza.
Quest'evento offre a CNS Pharmaceuticals l'opportunità di mostrare i suoi sviluppi nei trattamenti per i tumori primari e metastatici, attirando potenzialmente l'interesse degli investitori e promuovendo connessioni nel settore.
CNS Pharmaceuticals (NASDAQ:CNSP), una empresa biofarmacéutica centrada en desarrollar nuevos tratamientos para el cáncer cerebral y del sistema nervioso central, ha anunciado su participación en el 24º Foro Anual Biotech en Europa. John Climaco, CEO de la compañía, tiene programada una presentación el miércoles 25 de septiembre de 2024, a la 1:55 PM CEST en Basilea, Suiza.
La presentación estará disponible como un video webcast a demanda para los asistentes registrados a través del portal de presentadores de la conferencia. Además, el equipo de gestión de la empresa estará disponible para reuniones individuales en persona con inversores calificados que asistan a la conferencia.
Este evento proporciona a CNS Pharmaceuticals una oportunidad para mostrar sus avances en tratamientos de cáncer primario y metastásico, atrayendo potencialmente el interés de los inversores y fomentando conexiones en la industria.
CNS Pharmaceuticals (NASDAQ:CNSP)는 뇌 및 중추 신경계 암에 대한 새로운 치료법 개발에 주력하는 생명공학 회사로, 제24회 유럽 생명공학 포럼에 참여한다고 발표했습니다. 존 클리마코 CEO는 2024년 9월 25일 수요일, 오후 1시 55분 CEST에 스위스 바젤에서 발표할 예정입니다.
발표는 등록된 참가자를 위해 회의 발표자 포털을 통해 주문형 비디오 웹캐스트로 제공됩니다. 또한, 회사의 경영진은 회의에 참석하는 자격 있는 투자자와의 대면 일대일 회의를 위해 대기할 것입니다.
이 이벤트는 CNS Pharmaceuticals에게 주요 및 전이성 암 치료에 대한 발전을 선보일 수 있는 기회를 제공하며, 잠재적으로 투자자의 관심을 유도하고 산업 연결을 강화하는 데 기여합니다.
CNS Pharmaceuticals (NASDAQ:CNSP), une entreprise biopharmaceutique axée sur le développement de nouveaux traitements pour les cancers du cerveau et du système nerveux central, a annoncé sa participation au 24ème Forum Annuel Biotech en Europe. John Climaco, le PDG de l’entreprise, doit présenter le mercredi 25 septembre 2024, à 13h55 CEST à Bâle, en Suisse.
La présentation sera disponible en tant que webinaire vidéo à la demande pour les participants enregistrés via le portail des conférenciers de la conférence. De plus, l’équipe de direction de l’entreprise sera disponible pour des réunions individuelles en personne avec des investisseurs qualifiés assistant à la conférence.
Cet événement offre à CNS Pharmaceuticals l'occasion de présenter ses avancées dans les traitements contre le cancer primaire et métastatique, attirant potentiellement l'intérêt des investisseurs et favorisant les connexions dans l'industrie.
CNS Pharmaceuticals (NASDAQ:CNSP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung neuartiger Behandlungen für Gehirn- und ZNS-Tumoren konzentriert, hat seine Teilnahme am 24. jährlichen Biotech-Forum in Europa angekündigt. John Climaco, der CEO des Unternehmens, wird voraussichtlich am Mittwoch, den 25. September 2024, um 13:55 Uhr CEST in Basel, Schweiz, präsentieren.
Die Präsentation wird als Video-Webcast auf Abruf für registrierte Teilnehmer über das Portal der Konferenzredner verfügbar sein. Darüber hinaus wird das Managementteam des Unternehmens für persönliche Einzelgespräche mit qualifizierten Investoren, die an der Konferenz teilnehmen, zur Verfügung stehen.
Diese Veranstaltung bietet CNS Pharmaceuticals die Möglichkeit, seine Entwicklungen in der Behandlung von primären und metastasierenden Krebserkrankungen zu präsentieren, wodurch potenziell das Interesse von Investoren geweckt und Branchenkontakte gefördert werden.
- None.
- None.
Webcast presentation on Wednesday, September 25th at 1:55 PM CEST
HOUSTON, TX / ACCESSWIRE / September 23, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the 24th Annual Biotech in Europe Forum on Wednesday, September 25, 2024 at 1:55 PM CEST in Basel, Switzerland.
In addition to the presentation, management will be available to participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. For more information, please visit the conference website.
A video webcast of the presentation will be available on demand for those registered to attend the event and can be accessed through the conference presenters portal.
About CNS Pharmaceuticals, Inc.
CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system. The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is currently in development for the treatment of a number of serious brain and CNS oncology indications including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
CONTACTS:
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
CNSP@jtcir.com
SOURCE: CNS Pharmaceuticals, Inc.
View the original press release on accesswire.com
FAQ
When and where is CNS Pharmaceuticals (CNSP) presenting at the Biotech in Europe Forum?
Who will be presenting for CNS Pharmaceuticals (CNSP) at the Biotech in Europe Forum?
Will there be a webcast of CNS Pharmaceuticals' (CNSP) presentation at the Biotech in Europe Forum?
What type of meetings will CNS Pharmaceuticals (CNSP) management be available for at the Biotech in Europe Forum?
What is the main focus of CNS Pharmaceuticals (CNSP) as mentioned in the press release?
